Drug intelligence / Profile preview

Stimus

Development stage: Phase 3
Lead developer: Nanogen
Modality: Recombinant Proteins and Enzymes
Administration: Subcutaneous, Intravenous

Overview

Stimus is a biological product developed by Nanogen Pharmaceutical Biotechnology Joint Stock Company. It is a biosimilar version of darbepoetin alfa, an erythropoiesis-stimulating agent (ESA). Stimus is administered subcutaneously or intravenously and is indicated for the treatment of anemia in patients with chronic kidney disease who are on dialysis. It works by stimulating the production of red blood cells, similar to the reference product Aranesp®.

Other names: Nanogen's Darbepoetin alfa

Targets

Erythropoietin Receptor

Beyond the preview

Go deeper on Stimus.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Stimus.

Explore the full profile